TEMPE, Ariz., Jan. 16, 2025 /PRNewswire/ — GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of a Series D financing round. GT Medical Technologies is an investment portfolio company of Desert Angels across multiple rounds of investment.
The financing was led by Evidity Health Capital, alongside new investor Accelmed Partners. Also participating were existing investors MVM Partners, Gilde Healthcare, and Medtech Venture Partners. The funds will accelerate the completion of the ROADS clinical study focused on GammaTile for newly diagnosed brain metastases and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs). In addition, the funds will support the continued commercialization of GammaTile®, the Company’s FDA-cleared bioresorbable radiotherapy implant for treating brain tumors.